The Cost of CME for Breast Cancer Treatment

There is an absolute disconnect from what you hear from colleagues and maybe it's regions of the US where I'm speaking to and talking with. We know I-Bruhtenib-plus-vineticlax is going to get to more MRD negative states than I-B Bruhtenib. Not anything that we didn't, but it kind of solidifies the biological differences between these two CLLs and their sensitivity to I-Bruttin plus-manetrix regimen. Then we can get into the triplet or quadruple TKIs for patients who have a very sensitive disease. And if your MRD positive, continuation therapy might be able to convert you